Lysol is a mental-health technology startup that combines microcurrent-based brain-wave synchronization with AI biosignal analysis to create digital therapeutics for conditions such as sleep disorders, depression, stress, dementia prevention, and chronic pain. Its flagship wearable line, “Sleepisol,” has sold more than 50,000 units across Korea, the United States, and Japan, and its Samsung Health-based app “SleepySol Bio” has been downloaded over 1.7 million times worldwide. The company recorded approximately ₩2.6 billion in revenue in 2025 and is targeting more than ₩6 billion in 2026. Lysol’s technology has undergone clinical trials at Seoul National University Bundang Hospital, with results published in SCI-level journals. Recent accolades include the CES 2025 Innovation Award and selection as a 2025 “Unicorn Star” by Korea’s Ministry of SMEs and Startups. With partnerships such as one with Funai Research Institute for Japan market entry and Hyundai Engineering & Construction for real-estate deployments, Lysol plans to launch new products like “DAYZER,” roll out a subscription model in 2026, and secure additional global certifications to fuel international expansion.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2026